Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to commercialize OCU400, its experimental modifier gene …
Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea Read More